Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 1.00 |
| ▸ | HTR3A | P46098 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546723 | 0.87 | HTR1A (0.78) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL546677 | 0.87 | HTR1A (0.77) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL546684 | 0.87 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL547488 | 0.87 | HTR1A (0.77) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL547068 | 0.87 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL547714 | 0.86 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Bromide SCHEMBL20360588 | 0.86 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL547667 | 0.84 | HTR1A (0.82) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27976827 | 0.84 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27550397 | 0.84 | HTR1A (0.71) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180200207-A1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR USE AS A PROMOTER OF SATELLITE CELLS SELF-RENEWAL AND/OR DIFFERENTIATION | Universite De Paris (FR) | 2018-07-19 | — | — | US | disclosed |
| US-9822086-B2 | Process for the preparation of vortioxetine salts | EGIS GYOGYSZERGYAR ZRT. (HU) | 2017-11-21 | — | — | US | disclosed |
| US-9708280-B2 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| US-9708280-B2 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| US-20170114034-A1 | PROCESS FOR THE PREPARATION OF VORTIOXETINE SALTS | EGIS GYOGYSZERGYAR ZRT. (HU) | 2017-04-27 | — | — | US | disclosed |
| EP-3099669-A1 | PROCESS FOR THE PREPARATION OF VORTIOXETINE SALTS | Egis Gyógyszergyár Zrt. (HU) | 2016-12-07 | — | — | EP | disclosed |
| US-20160137620-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | H. LUNDBECK A/S (DK) | 2016-05-19 | — | — | US | disclosed |
| WO-2015114395-A1 | PROCESS FOR THE PREPARATION OF VORTIOXETINE SALTS | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2015-08-06 | — | — | WO | disclosed |
| US-9090575-B2 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2015-07-28 | — | — | US | disclosed |
| US-20150110873-A1 | ENTERIC TABLET | TAKEDA PHARMACEUTICAL (JP) | 2015-04-23 | — | — | US | disclosed |
| US-20140163043-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2014-06-12 | — | — | US | disclosed |
| US-20130115292-A1 | ENTERIC TABLET | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2564838-A1 | ENTERIC TABLET | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114034-A1 | PROCESS FOR THE PREPARATION OF VORTIOXETINE SALTS | SLC6A4, SLC6A2, SLC6A3 | HTR1A 106/4885HTR3A 138/4885CYP1A2 230/4885 |
| US-20140163043-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885CYP1A2 309/4885 |
| US-20180200207-A1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR USE AS A PROMOTER OF SATELLITE CELLS SELF-RENEWAL AND/OR DIFFERENTIATION | CHRNB1, HTR1B, CHRNB2 | HTR1A 5/4885HTR3A 14/4885CYP1A2 3565/4885 |
| US-20160137620-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885CYP1A2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.